Review: Opportunities and barriers for omics-based biomarker discovery in steatotic liver diseases.

Thiele M, Villesen IF, Niu L, Johansen S, Sulek K, Nishijima S, Van Espen L, Keller M, Israelsen M, Suvitaival T, de Zawadzki A, Juel HB, Brol MJ, Stinson SE, Huang Y, Alvarez Silva MC, Kuhn M, Anastasiadou E, Leeming DJ, Karsdal M, Matthijnssens J, Arumugam M, Dalgaard LT, Legido-Quigley C, Mann M, Trebicka J, Bork P, Jensen LJ, Hansen T, Krag A, MicrobLiver and GALAXY consortia, GALAXY consortium, MicrobLiver consortium

Journal of hepatology, 2024

doi:10.1016/j.jhep.2024.03.035.

Terlipressin therapy is associated with increased risk of colonisation with multidrug-resistant bacteria in patients with decompensated cirrhosis.

Mücke MM, Hernández-Tejero M, Gu W, Kuhn M, Janz M, Keller MI, Fullam A, Altepeter L, Mücke VT, Finkelmeier F, Schwarzkopf KM, Cremonese C, Hunyady PM, Heilani MW, Uschner FE, Schierwagen R, Brol MJ, Fischer J, Klein S, Peiffer KH, Hogardt M, Shoaie S, Coenraad MJ, Bojunga J, Arroyo V, Zeuzem S, Kempf VAJ, Welsch C, Laleman W, Bork P, Fernandez J, Trebicka J, MICROB-PREDICT and PREDICT Study Group of the EASL-CLIF Consortium

Alimentary Pharmacology and Therapeutics, 2024

doi:10.1111/apt.17899.

Enterotypes of the human gut mycobiome.

Lai S, Yan Y, Pu Y, Lin S, Qiu JG, Jiang BH, Keller MI, Wang M, Bork P, Chen WH, Zheng Y, Zhao XM

Microbiome, 2023

doi:10.1186/s40168-023-01586-y.

Cultivation-independent genomes greatly expand taxonomic-profiling capabilities of mOTUs across various environments.

Ruscheweyh HJ, Milanese A, Paoli L, Karcher N, Clayssen Q, Keller MI, Wirbel J, Bork P, Mende DR, Zeller G, Sunagawa S

Microbiome, 2022

doi:10.1186/s40168-022-01410-z.

Microbial genomes from non-human primate gut metagenomes expand the primate-associated bacterial tree of life with over 1000 novel species.

Manara S, Asnicar F, Beghini F, Bazzani D, Cumbo F, Zolfo M, Nigro E, Karcher N, Manghi P, Metzger MI, Pasolli E, Segata N

GENOME BIOLOGY, 2019

doi:10.1186/s13059-019-1923-9.